Overview

• A new compound, FEM-1689, targets a protein involved in neuropathic pain, showing significant pain reduction in mouse trials.
• FEM-1689 does not interact with opioid receptors, reducing the risk of addiction associated with current pain medications.
• The compound also regulates the integrated stress response (ISR), which is crucial for the body's healing process.
• NuvoNuro Inc., co-founded by researchers, received NIH funding to develop FEM-1689 into a drug for clinical use.
• The research represents a significant step forward in the search for effective, non-addictive pain treatments.